Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Participates in UK 100,000 Genomes Project

October 1, 2019 11:50:50
  • The main subsidiary of POAI partnered with Genomics England for the groundbreaking UK 100,000 Genomes Project
  • POAI is positioned on the cutting edge of future cancer treatments
  • The company’s AI-driven platforms are improving cancer patient outcomes and setting a new standard in the industry

For years, cancer treatment has involved human beings playing the role of guinea pigs. Oncologists have become quite adept at diagnosing specific types of cancer, but they mostly lack the data to know which drugs will be most effective in fighting patients’ specific cancer types. Patients leave doctors’ offices hopeful but worried, gambling their recovery on the power of the prescription they received. This is the cancer treatment of today. However, the future of cancer treatment could be transformed with the innovative technologies of Predictive Oncology Inc. (NASDAQ: POAI), a company developing highly customizable assessment methods for cancer patients to guide personalized treatments.

As part of Predictive Oncology’s commitment to determining the best pathways for more individualized and effective cancer treatment, one of its main subsidiaries – Helomics – partnered with the UK 100,000 Genomes Project (“UK100K”) in a research study focused on driving precision medicine to help conquer…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com